Structures, targets and recent approaches in anti-leishmanial drug discovery and development.


Seifert, K; (2011) Structures, targets and recent approaches in anti-leishmanial drug discovery and development. Open Med Chem J, 5. pp. 31-9. ISSN 1874-1045 DOI: 10.2174/1874104501105010031

[img]
Preview
Text - Published Version
License:

Download (199Kb) | Preview

Abstract

Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 2002. Combination therapy is now explored in clinical trials as a new treatment approach for VL to reduce the length of treatment and potentially prevent selection of resistant parasites. However there is still a need for new drugs due to safety, resistance, stability and cost issues with existing therapies. The search for topical treatments for cutaneous leishmaniasis (CL) is ongoing. This review gives a brief overview of recent developments and approaches in anti-leishmanial drug discovery and development.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Immunology and Infection
Research Centre: Antimicrobial Resistance Centre (AMR)
Leishmaniasis Group
Neglected Tropical Diseases Network
PubMed ID: 21629509
URI: http://researchonline.lshtm.ac.uk/id/eprint/679

Statistics


Download activity - last 12 months
Downloads since deposit
320Downloads
319Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item